Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia

Tyrosine kinase inhibitors specific for BCR-ABL, were a major breakthrough in CML therapy. Second generation tyrosine kinase inhibitors (dasatinib, nilotinib) are indicated for imatinib resistant and intolerant patients. Present guidelines recommend continuous drug dosing for maintaining remission....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Gadó, Klára, Matolcsy, András, Csomor, Judit, Kicsi, Dóra, Bödör, Csaba, Domján, Gyula
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2012
Gaiak:
Letter to the Editor
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3514089/
https://ncbi.nlm.nih.gov/pubmed/23210842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2162-3619-1-17
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak